DRIO

DarioHealth Corp. (DRIO) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. DarioHealth Corp. is a global digital therapeutics (DTx) company providing personalized, evidence-based interventions for chronic conditions (diabetes, hypertension, weight management) and behavioral health. The company operates as a single reporting segment with significant operations in the U.S., Israel, and India. Following the acquisition of Twill, Inc. in February 2024, the company continues to integrate its digital health platform.

Key Financial Metrics (Six Months Ended June 30, 2025)

Material Changes vs. Prior Period

• Revenue: Increased 0.9% year-over-year (YoY) for the six months ended June 30, 2025 ($12.1M vs. $12.0M), driven by growth in the Consumer channel, offset by a decline in the Pharma channel.
• Cost of Revenues: Decreased 22.7% YoY to $5.3M, primarily due to reduced amortization of acquired technology and lower payroll expenses.
• Gross Margin: Improved significantly to 56.5% (from 43.2% in the prior year period) due to revenue mix changes and cost efficiencies.
• Operating Expenses: Total operating expenses decreased 35.1% YoY to $25.5M. R&D expenses dropped 41.8%, Sales & Marketing dropped 20.9%, and G&A dropped 44.4%, largely attributed to post-merger integration efficiencies and reduced stock-based compensation.
• Financial Expenses: Net financial expenses increased significantly to $3.6M (from a net income of $11.3M in the prior year), driven by the revaluation of pre-funded warrants and long-term loan fair value adjustments.
• Debt Refinancing: The company refinanced its previous Avenue Loan Facility with a new $32.5M Callodine Loan Facility in April 2025, maturing in 2030.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: Management states that current cash on hand is insufficient to fund projected operating requirements for the next 12 months. This raises substantial doubt about the company's ability to continue as a going concern.
• Debt Covenant Breach: As of June 30, 2025, the company did not meet a financial covenant under the new Callodine Credit Agreement. The company has notified the lender of its intention to utilize an "Equity Cure" to address the default, which requires raising capital equal to 150% of the breached amount by November 15, 2025.
• Equity Dilution: Significant equity activity occurred, including the conversion of Series D preferred stock into over 33 million common shares and the issuance of warrants in connection with the new debt facility. Stockholders approved an increase in authorized common stock from 160 million to 400 million shares.
• Geopolitical Risk: The company highlights risks related to military conflict in Israel, where key operations and executive officers are located, including potential disruptions to supply chains and employee availability.
• Nasdaq Compliance: The company is in a compliance period to regain compliance with Nasdaq's minimum bid price requirement ($1.00 per share) by September 15, 2025, or face delisting.

Investor Verification Checklist

• Capital Raise Status: Verify if the company has successfully executed the "Equity Cure" or secured additional financing to satisfy the Callodine debt covenant by the November 15, 2025 deadline.
• Going Concern Mitigation: Assess the timeline and probability of achieving profitability or securing sufficient funding to resolve the substantial doubt regarding the company's ability to continue operations.
• Stock Price Volatility: Monitor the common stock price relative to the $1.00 Nasdaq minimum bid price requirement and the potential for a stock split or delisting.
• Revenue Concentration: Review the dependency on the major customer (10.6% of YTD revenue) and the stability of the B2B2C contracts.
• Warrant Liability Impact: Evaluate the volatility of the $3.4M warrant liability and its potential to cause significant non-cash fluctuations in future net loss figures.